Search clinical trials for: ADP inhibitor

Total 68207 results

University of California, Irvine
Eurofins Viracor

Not yet recruiting

Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla

CMV | Allogeneic Stem Cell Transplantation

United States
Ruijin Hospital

Not yet recruiting

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Hematologic Malignancy
The First Hospital of Jilin University

Not yet recruiting

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Platinum-sensitive Relapsed Ovarian Cancer
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
Anhui Provincial Hospital

Recruiting

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Cytomegalovirus Infection Reactivation

China
Cantonal Hospital Graubuenden
University of Zurich

Not yet recruiting

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease (SIDIA)

Autosomal Dominant Polycystic Kidney Disease

Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Ovarian Cancer

United States, Germany
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
University of Miami
GlaxoSmithKline

Not yet recruiting

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Ovarian Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial Carcinoma | Recurrent or Metastatic | TP53 Mutation

China
University of Wisconsin, Madison
Merck Sharp & Dohme LLC

Not yet recruiting

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Kidney Transplant Infection | Cytomegalovirus Infections | Pancreas Transplant

United States
Qian Qin
Janssen, LP; UT Southwestern Comprehensive Cancer Center

Not yet recruiting

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | CHEK2 Gene Mutation | FANCA Gene Mutation | RAD51B Gene Mutation | RAD54L Gene Mutation | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Deleterious HRR Gene Mutation
Ivy Brain Tumor Center
GlaxoSmithKline

Not yet recruiting

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Glioblastoma | Brain Tumor | GBM | Brain Neoplasms, Adult, Malignant
The First Affiliated Hospital of Xiamen University

Recruiting

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (SEGNO)

Oligometastatic Prostate Cancer | Locally Advanced Prostate Cancer

China
Vall d'Hebron Institute of Oncology

Recruiting

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE)

Ovarian Cancer

Spain
Ibrahim Halil Sahin
GlaxoSmithKline

Not yet recruiting

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

MMR-D/MSI-H Colorectal Cancers

United States
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant

Israel, Taiwan, Australia, Korea, Republic of
Hospital do Rim e Hipertensão

Not yet recruiting

Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

CMV Infection
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections (LUCY-1)

Cytomegalovirus Infection

France
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
Cao Weijie

Recruiting

Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Letemovir for the Prevention of CMV Infection After Allo-HSCT

China
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
Armando Santoro, MD
GlaxoSmithKline; Istituto Clinico Humanitas

Not yet recruiting

Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001)

Glioma, Malignant

Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Female Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT)

Triple Negative Breast Cancer

United States
Korea University Anam Hospital
Takeda; Korean Cancer Study Group

Not yet recruiting

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Efficacy
Fox Chase Cancer Center

Recruiting

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Essential Thrombocytosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Sichuan University

Recruiting

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer | Extensive-stage Small-cell Lung Cancer

China
University of Maryland, Baltimore
Janssen Scientific Affairs, LLC

Recruiting

High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS)

Prostate Cancer | Oligometastatic Disease

United States
Risen (Suzhou) Pharma Tech Co., Ltd.

Recruiting

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Advanced Solid Tumors

China
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)

Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab

China
Erasmus Medical Center
University Medical Center Groningen; Leiden University Medical Center

Recruiting

FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE)

Advanced Breast Cancer

Netherlands
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Ovarian Cancer
MedSIR

Not yet recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA)

Ovarian Cancer | Oligometastatic Disease | Serous Ovarian Tumor
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
Haider Mahdi
GlaxoSmithKline; Zenith Epigenetics

Recruiting

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Ovarian Cancer | Recurrent Solid Tumors

United States
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Peking University Cancer Hospital & Institute

Recruiting

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab (BRAND)

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

China
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.

Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Advanced Solid Tumor | Non-small Cell Lung Cancers

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
Mario Negri Institute for Pharmacological Research
AstraZeneca

Recruiting

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients (IOLANTHE)

Carcinoma, Ovarian Epithelial

Italy
Alexander B Olawaiye, MD
AstraZeneca

Recruiting

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Ovarian Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Not yet recruiting

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc)

Cancer

France
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

China, United States, Italy, Spain, United Kingdom, Korea, Republic of, Canada, Germany, Poland, Belgium, Japan, Vietnam, Bulgaria, France, Brazil, India, Malaysia, Taiwan, Thailand, Hungary, Australia, Austria, Turkey, Hong Kong, Switz... and more

Search clinical trials for: ADP inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations